Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis remains...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:ESMO Open
Hoofdauteurs: Morgillo, Floriana, Della Corte, Carminia Maria, Fasano, Morena, Ciardiello, Fortunato
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2016
Onderwerpen:
Review
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5070275/
https://ncbi.nlm.nih.gov/pubmed/27843613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000060
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items